Wegovy First Month Results: What to Expect in the Early Weeks

The decision most people are sitting with: is early slow progress a bad sign?

A lot of people start Wegovy expecting the first month to look like the trial results condensed into four weeks. It rarely does, and that gap between expectation and experience is where doubt creeps in. The decision this page is really about is whether slow early progress means something is wrong, or whether it reflects how the medicine is designed to work.

The short answer is that modest movement in month one is normal by design. Wegovy's titration schedule begins at 0.25 mg weekly, a dose that exists primarily to let your body adjust to the GLP-1 mechanism before the therapeutic steps begin. A prescriber moves the dose up roughly every four weeks, stepping through 0.5 mg and 1.0 mg before reaching 1.7 mg and eventually the 2.4 mg maintenance dose. Weight loss tends to accelerate as the dose climbs. Expecting 15% loss at 0.25 mg is a bit like expecting to be warm the moment you turn the heating on.

People who see very little change in week one sometimes assume the medicine is not working for them. That concern is understandable, and worth raising with your prescriber, but a quiet first week is not evidence of treatment failure. What actually happens in the first week of Wegovy is a useful reference if you are right at the beginning of this experience, and if you want to understand the broader pattern of how things tend to unfold, our guide to the first month of Wegovy covers what most people experience across all four weeks. Patience at this stage is not passive; it is the appropriate clinical response to a planned titration.

What the trial evidence actually says about early weight loss

The STEP 1 trial, published in the New England Journal of Medicine, followed adults taking semaglutide 2.4 mg for 68 weeks alongside lifestyle support. Average body-weight reduction across that period was around 15%. The trial did not report the month-one figure as a separate headline, which is itself instructive: the clinical significance of semaglutide is measured over more than a year, not four weeks.

Published data from longer follow-up periods generally shows that the steepest rate of weight loss lands in the middle months of treatment (roughly weeks 12 to 36) once people reach the maintenance dose. By month one most participants would still be on 0.25 mg or 0.5 mg. Real-world reports and the STEP programme's trajectory data suggest an average loss at the four-week mark is likely in the 1–3% range for body weight, though some people lose more and some see almost no movement yet.

It is worth noting that results at two months tend to be noticeably more pronounced once the dose has begun to move upward, which gives a clearer signal about individual response. The NHS patient information on semaglutide notes that the medicine works by reducing appetite and slowing gastric emptying, the NHS semaglutide page outlines how it works and what to expect.

Side effects in month one: what is typical and when to act

The first month is often when side effects are most noticeable, and managing them well can make a real difference to how the rest of treatment goes. The most common are gastrointestinal: nausea, loose stools, constipation, indigestion and a feeling of fullness that can make eating feel effortful. For most people these settle within one to two weeks. Eating smaller portions, avoiding rich or fatty food and staying well hydrated all help.

A common misconception is that nausea means the medicine is harming you. It is uncomfortable, but it is also the expected biological response to a GLP-1 receptor agonist slowing gastric emptying. If nausea is severe or persistent, that is a conversation to have with your prescriber, not a reason to quietly stop. Stopping abruptly and restarting can reset tolerability.

There are symptoms that do need prompt medical attention: severe abdominal pain that radiates to the back (a warning sign for pancreatitis), signs of a serious allergic reaction, or significant worsening of mood. If any of these occur, seek medical help rather than waiting for your next appointment. The MHRA monitors GLP-1 medicines closely and patients can report unexpected side effects directly via the Yellow Card scheme. Details of what to watch for more broadly are covered in our Wegovy treatment guide.

How to use month one wisely

If the first four weeks are not going to deliver the headline numbers, what are they actually for? They are the settling-in period: your body is adapting to a new appetite signal, your prescriber is watching for tolerability, and the habits that will carry you through the next year are forming now. This is also the window where practical questions tend to cluster, how to store the pen correctly, whether the injection site matters, what to eat when nothing appeals.

For people considering Wegovy privately, a realistic timeline for when Wegovy takes effect helps calibrate expectations before the first pen arrives. And if you want to understand what that later journey can look like, the fuller picture of first-month progress gives useful context. Our clinical team at nume reviews every consultation personally (the same day it is submitted) so any concerns you raise at the start of treatment reach a real prescriber, not a triage queue.

If Wegovy is something you are actively exploring, you can read about how a consultation with our prescribers works and what the process involves. There is no pressure at that stage, it is an assessment, and the prescriber makes the clinical call.